



## ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

March 31, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 31, 2022-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET.

A webcast of the panel will be accessible through the “Investors and Media” section of the Company’s website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay will be available at the same location.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20220331005315/en/>

### INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting

Robert Stanislaro

212-850-5657

[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen, Inc.